ARS Pharmaceuticals Inc (NASDAQ: SPRY) started the day on Thursday, with a price decrease of -4.40% at $12.81, before settling in for the price of $13.40 at the close. Taking a more long-term approach, SPRY posted a 52-week range of $2.55-$16.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -34.76%. Meanwhile, its Annual Earning per share during the time was -1.44%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -12.72%. This publicly-traded company’s shares outstanding now amounts to $96.41 million, simultaneously with a float of $47.59 million. The organization now has a market capitalization sitting at $1.24 billion. At the time of writing, stock’s 50-day Moving Average stood at $10.36, while the 200-day Moving Average is $8.08.
ARS Pharmaceuticals Inc (SPRY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. ARS Pharmaceuticals Inc’s current insider ownership accounts for 50.91%, in contrast to 37.73% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’24, this organization’s Chief Operating Officer sold 50,000 shares at the rate of 15.00, making the entire transaction reach 750,000 in total value, affecting insider ownership by 6,024. Preceding that transaction, on Aug 19 ’24, Company’s Chief Commercial Officer sold 10,000 for 14.00, making the whole transaction’s value amount to 140,000. This particular insider is now the holder of 5,693 in total.
ARS Pharmaceuticals Inc (SPRY) Earnings and Revenue Records
ARS Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -12.72% and is forecasted to reach -0.86 in the upcoming year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Let’s observe the current performance indicators for ARS Pharmaceuticals Inc (SPRY). It’s Quick Ratio in the last reported quarter now stands at 32.78. The Stock has managed to achieve an average true range (ATR) of 1.03. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2483.60.
In the same vein, SPRY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.47, a figure that is expected to reach -0.14 in the next quarter, and analysts are predicting that it will be -0.86 at the market close of one year from today.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
If we take a close look at the recent performances of ARS Pharmaceuticals Inc (NASDAQ: SPRY), its last 5-days Average volume was 2.25 million that shows progress from its year to date volume of 0.71 million. During the previous 9 days, stock’s Stochastic %D was recorded 56.12% While, its Average True Range was 1.16.
Raw Stochastic average of ARS Pharmaceuticals Inc (SPRY) in the period of the previous 100 days is set at 58.77%, which indicates a major rise in contrast to 51.41% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 109.80% that was higher than 63.93% volatility it exhibited in the past 100-days period.
